Irritable bowel syndrome symptom severity improves equally with probiotic and placebo

Show full item record



Permalink

http://hdl.handle.net/10138/174086

Citation

Lyra , A , Hillilä , M , Huttunen , T , Mannikko , S , Taalikka , M , Tennila , J , Tarpila , A , Lahtinen , S , Ouwehand , A C & Veijola , L 2016 , ' Irritable bowel syndrome symptom severity improves equally with probiotic and placebo ' , World Journal of Gastroenterology , vol. 22 , no. 48 , pp. 10631-10642 . https://doi.org/10.3748/wjg.v22.i48.10631

Title: Irritable bowel syndrome symptom severity improves equally with probiotic and placebo
Author: Lyra, Anna; Hillilä, Markku; Huttunen, Teppo; Mannikko, Sofia; Taalikka, Mikko; Tennila, Julia; Tarpila, Anneli; Lahtinen, Sampo; Ouwehand, Arthur C.; Veijola, Lea
Contributor: University of Helsinki, Department of Medicine
Date: 2016-12-28
Language: eng
Number of pages: 12
Belongs to series: World Journal of Gastroenterology
ISSN: 1007-9327
URI: http://hdl.handle.net/10138/174086
Abstract: AIM To determine the effects of Lactobacillus acidophilus NCFM on irritable bowel syndrome (IBS) symptoms and quality of life (QoL). METHODS In this randomized triple-blind trial, adult IBS volunteers who were recruited according to Rome. criteria received 109 or 1010 colony-forming units of NCFM or placebo daily for 12 wk. IBS Symptom Severity Score (IBS-SSS), which constituted the primary outcome, and secondary outcomes, including individual IBS symptoms, IBS-related QoL questionnaire, anxiety and depression, defecation frequency, and stool consistency, were assessed at baseline at the end of the 8-wk runin period, after 4 and 12 wk of intervention, and after a 4-wk washout. RESULTS A total of 340 of 391 randomized volunteers completed the trial. IBS-SSS improved over 12 wk of treatment in all treatment groups, decreasing by a mean +/- SD of 44.0 +/- 80.2, 50.8 +/- 82.4, and 48.3 +/- 72.2 in the placebo, active low-dose, and active high-dose groups, respectively. Similarly, secondary outcomes did not differ between treatment groups. However, in a post hoc analysis of volunteers with moderate to severe abdominal pain at baseline (VAS > 35/100), the treatment significantly reduced the sensation of abdominal pain. Pain scores fell by 20.8 +/- 22.8, 29.4 +/- 17.9, and 31.2 +/- 21.9 in the placebo, active low-dose, and active high-dose groups, respectively (P value for placebo vs combined active doses = 0.0460). CONCLUSION NCFM alleviates moderate to severe abdominal pain, consistent with earlier observations of this strain mitigating visceral pain through increased analgesic receptor expression.
Subject: Irritable bowel syndrome
Functional bowel disorder
Symptom questionnaire
Quality of life
Visceral pain
Abdominal pain
Lactobacillus acidophilus
Probiotic
Intervention
LACTOBACILLUS-ACIDOPHILUS NCFM
GUT-BRAIN AXIS
DOUBLE-BLIND
CLINICAL-TRIAL
MICROBIOTA
PAIN
POPULATION
VALIDATION
PREBIOTICS
DISORDERS
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Irritable_bowel_syndrome_symptom.pdf 1.094Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record